Clinical trials
for patients
Learn about available clinical trials
-
February 25, 2025Pamplona/MadridIn recruitment
IELSG48 Phase 3 clinical trial comparing rituximab plus zanubrutinib with rituximab monotherapy in previously untreated symptomatic splenic marginal zone lymphoma
The aim of this clinical trial is to compare the efficacy and tolerability of the combination of two drugs, rituximab and zanubrutinib, compared to rituximab monotherapy in patients with previously untreated splenic marginal zone lymphoma (SMZL) requiring systemic treatment. -
February 25, 2025PamplonaIn recruitment
-
February 25, 2025PamplonaIn recruitmentEarly phase
ASK-CHF2-CS201 Phase 2, adaptive, clinical trial to evaluate the efficacy of intracoronary infusion of AB-1002 in adult subjects with NYHA functional class III heart failure and GenePHIT
The aim of the ASK-CHF2-CS201 clinical trial is to evaluate the safety and efficacy of AB-1002 for the treatment of patients with heart failure and non-ischemic cardiomyopathy. -
February 25, 2025PamplonaIn recruitment
GCT1078-01 Clinical trial of GEN1078 in participants with malignant solid tumors.
The aim of this study is to find out if the trial drug is safe in participants with certain types of cancer and to find out what is the best dose. -
February 24, 2025Pamplona/MadridIn recruitment
TT420C2308 Study to evaluate the efficacy and safety of oral tinengotinib compared to physician's choice in subjects with recurrent/resistant fibroblast growth factor receptor (FGFR)-disrupted cholangiocarcinoma ...
The main goal of this study is to find out how well tinengotinib works and how safe tinengotinib is compared to the study doctor's choice of chemotherapy treatment. This study will be divided into 2 parts: Part A and Part B. The purpose of Part A of the study will be to determine the best dose of tinengotinib to use in Part B of the study. The purpose of Part B is to get more information about how tinengotinib works and its safety compared to the study doctor's choice of treatment. -
February 24, 2025PamplonaIn recruitment
ACT18421 Randomized, double-blind, placebo-controlled proof-of-concept (PoC) study to evaluate the efficacy, safety and tolerability of itepekimab in participants with inadequately controlled chronic rhinosinusitis without nasal polyps.
The main objective of this study is to test the effects of itepekimab in patients with chronic rhinosinusitis without nasal polyps who are already using corticosteroid nasal sprays. -
February 24, 2025Pamplona/MadridIn recruitment
D7020C00001 Clinical trial of the anti-TIGIT/anti-PD-1 bispecific antibody AZD2936 in patients with advanced or metastatic non-small cell lung cancer.
The objective of this study is to learn more about AZD2936, a new antibody that blocks two proteins (PD-1 and TIGIT) at the same time. AZD2936 can be used if unresectable or metastatic non-small cell lung cancer has been diagnosed. The main objective of this study is to gather information on the correct dose of AZD2936 and to understand whether this new drug can be useful for the treatment of the diagnosed disease. Both PD-1 and TIGIT are called "immune checkpoints". They emit signals ... -
February 18, 2025Pamplona/MadridIn recruitment
D8470C00001 Phase I/IIa clinical trial to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of AZD8421 alone or in combination in patients with selected advanced or metastatic solid tumors (CYCAD-1)
El objetivo es investigar la seguridad y tolerabilidad, caracterizar los DLT y determinar la DMT y/o DMF y/o dosis recomendada dosis recomendada de fase II (RP2D) de AZD8421 como monoterapia y también en combinación con otros medicamentos contra el cáncer. -
February 18, 2025Pamplona/MadridIn recruitment
SLN124-004 Phase I/II clinical trial of SLN124 in patients with polycythemia vera with an open-label dose-escalation phase followed by a randomized double-blind phase.
The main objective is to evaluate the safety and tolerability of single and multiple subcutaneous (s.c.) doses of SLN124 in patients with polycythemia vera (PV). -
February 18, 2025PamplonaIn recruitment
IVY-P3-24-021 Phase III, open-label, randomized, 2-group clinical trial to compare the clinical efficacy and safety of niraparib with temozolomide in adult participants with newly diagnosed MGMT-unmethylated glioblastoma
This is a Phase III trial. This trial includes: Phase 1, in which the trial drug or comparator drug will be taken and all participants will also receive radiotherapy; and Phase 2, in which they will continue with the same drug they were given in Phase 1 without radiotherapy.